Pseudoprogression following chemoradiotherapy for glioblastoma multiforme

Canadian Journal of Neurological Sciences

Volumn 37, Issue 1, 2010, Pages 36-42

  Sanghera, Paul ^a,b,d,e   Perry, James ^a,b,d   Sahgal, Arjun ^a,b,d   Symons, Sean ^b,d   Aviv, Richard ^a,d   Morrison, Meredith ^a,d   Lam, Kelvin ^c   Davey, Phillip ^a,b,d   Tsao, May N ^a,b,d  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; DRUG RESPONSE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIATION RESPONSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 76649113101     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100009628     Document Type: Article

References (23)

1. Jones B, Sanghera P. Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma. Int J Radiat Oncol Biol Phys. 2007;68:441-448
2. Paszat L, Laperriere N, Groome P, Schulze K, Mackillop W, Holowaty E. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51:100-107
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987-996
4. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008; 9:453-461
5. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63:535-537
6. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192-2197
7. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PS, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008;113:405-410
8. Jefferies S, Burton K, Jones P, Burnet N. Interpretation of early imaging after concurrent radiotherapy and temozolomide for Glioblastoma [abstract]. Clin Oncol. 2007;19:S33.
9. Clarke JL, Abrey LE, Karimi S, Lassman AB. Pseudoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM) [abstract]. J Clin Oncol. 2008;26:2025.
10. Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. Epub 2009 Feb 17.
11. Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol. Epub 2009 Jan 14.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216
13. Shah GD, Kesari S, Xu R, Batchelor TT, O'Neill AM, Hochberg FH, et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol. 2006;8:38-46.
14. Burnet NG, Lynch AG, Jefferies SJ, Price SJ, Jones PH, Antoun NM, et al. High grade glioma: imaging combined with pathological grade defines management and predicts prognosis. Radiother Oncol. 2007;85:371-378
15. Mason WP, Maestro RD, Eisenstat D, Forsyth P, Fulton D, Laperriere N, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol. 2007;14:110-117
16. Perry JR, Cairncross JG. Glioma therapies: how to tell which work? J Clin Oncol. 2003;21:3547-3549
17. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280
18. Weller M, Yung WK. Bevacizumab--news from the fast lane? Neuro Oncol. 2008;10:647.
19. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25: 4722-4729
20. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;10;27:740-745
21. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66:1258-1260
22. Perry JR, Mason WP, Belanger K, Kavan P, Fulton D, Easaw J, et al. The temozolomide RESCUE study: a phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma [abstract]. J Clin Oncol. 2008; 26:2010.
23. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007;82:81-83